Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum
Open Access
- 1 October 2015
- journal article
- Published by Elsevier in EBioMedicine
- Vol. 2 (10) , 1507-1512
Abstract
No abstract availableKeywords
Funding Information
- Scottish Enterprise Encompass Kick Start (KSB001)
This publication has 23 references indexed in Scilit:
- Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosisOrphanet Journal of Rare Diseases, 2014
- Nutritional Cues ControlPseudomonas aeruginosaMulticellular Behavior in Cystic Fibrosis SputumJournal of Bacteriology, 2007
- Patient-reported Outcomes in Cystic FibrosisProceedings of the American Thoracic Society, 2007
- Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control studyJournal of Cystic Fibrosis, 2006
- Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosisThorax, 2004
- Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patientsJournal of Cystic Fibrosis, 2003
- Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatric Pulmonology, 2002
- Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic.Thorax, 1996
- Pantetheinase Activity and Cysteamine Content in Cystinotic and Normal Fibroblasts and LeukocytesPediatric Research, 1981
- In-vitro activity of antimicrobial agents against Neisseria gonorrhoeae in Brussels.Sexually Transmitted Infections, 1978